Abacavir/dolutegravir/lamivudine Hetero
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Hetero Drugs South Africa (Pty) Ltd | Abacavir/dolutegravir/lamivudine hetero | Not stated | 550339.338 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Abacavir/dolutegravir/lamivudine hetero EACH TABLET CONTAINS ABACAVIR 600,0 mg DOLUTEGRAVIR SODIUM EQUIVALENT TO DOLUTEGRAVIR 50,0 mg LAMIVUDINE 300,0 mg | Not listed | 550339.33855/20.2.8/0339.338 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Abacavir
Consolidated Schedules 06 July 2026, line 5118
S4: Dolutegravir
Consolidated Schedules 06 July 2026, line 6100
S4: Lamivudine
Consolidated Schedules 06 July 2026, line 6850
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.